4
Changes in Ownership
Avalo Therapeutics, Inc. Filed Acc 0001677896-26-000004
Chief Legal Officer sold 75,063 shares at an average $20.17 ($1,513,673)
- Chief Legal Officer acquired 75,063 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
VARKI PAUL · Chief Legal Officer
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-05-06 | Exercise or conversion : show line 1 in the form 10b5-1 | +62,500 | $13.43 | $839,375 | 66,134 | D |
| 2026-05-06 | Exercise or conversion : show line 2 in the form 10b5-1 | +12,563 | $8.04 | $101,007 | 78,697 | D |
| 2026-05-06 | Sale : show line 3 in the form 10b5-1 | −37,375 | $18.91 | $706,836 | 41,322 | D |
| 2026-05-06 | Sale : show line 4 in the form 10b5-1 | −5,196 | $19.78 | $102,783 | 36,126 | D |
| 2026-05-06 | Sale : show line 5 in the form 10b5-1 | −22,839 | $21.22 | $484,541 | 13,287 | D |
| 2026-05-06 | Sale : show line 6 in the form 10b5-1 | −9,253 | $22.70 | $210,029 | 4,034 | D |
| 2026-05-06 | Sale : show line 7 in the form 10b5-1 | −400 | $23.71 | $9,484 | 3,634 | D |
| Open-market sales · 75,063 sh · avg $20.17 · $1,513,673 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-05-06 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) | −62,500 | 87,500 | D |
| 2026-05-06 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) | −12,563 | 87,437 | D |
Loading xslF345X06/form4-05072026_080504.xml…